The Department of Veterans Affairs (VA) seeks proposals for a firm-fixed-price contract to supply radiopharmaceuticals to the VA Loma Linda Healthcare System. The goal is to procure a comprehensive range of these specialized pharmaceuticals for use in nuclear medicine and imaging services over a four-year period, with the potential for a one-year extension.
The VA aims to purchase a diverse array of products, including FDG, NAF, Sodium Iodine, In-111 Pentetreotide, and Tc-99m-based formulations, among others. These medications are subject to stringent quality and packaging regulations and must be delivered within specific timelines.
The scope of work for the awardee will involve fulfilling orders and delivering the requested quantities of these pharmaceuticals to the healthcare system. Attention to detail is paramount, given the specialized nature of the products and their applications.
Eligible applicants should possess the capabilities and expertise to meet the VA's specialized pharmaceutical needs. Experience in the industry and a track record of adhering to high-quality standards are essential.
Funding for this contract is estimated at up to $5 million, encompassing the base year and optional periods. The contract type is firm-fixed-price. Offerors must submit their quotes, including pricing structures, by the extended response deadline of 8 August 2024, 10:00 AM Pacific Time, as stated in Amendment 0002.
The VA will evaluate applications based on their ability to meet the specified pharmaceutical requirements, with consideration given to product quality, adherence to technical specifications, and cost effectiveness.
For clarification or questions, interested parties can contact Contract Specialist Hestia Sim at Hestia.Sim@va.gov.
This opportunity seeks to ensure a reliable supply of essential radiopharmaceuticals for the VA Loma Linda Healthcare System, emphasizing careful consideration of the product's unique nature and associated regulations.